We'd like your feedback
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.
Eleanour
Quek
e.quek@imperial.ac.uk.uk
salman
siddiqui
s.siddiqui@imperial.ac.uk
Chronic lower respiratory diseases
This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.
Asthma is the most common respiratory disease affecting adults and children. It presents with symptoms of cough, wheeze and breathlessness, and results from inflammation of the airways, narrowing and hyper-reactivity to triggers. Despite its prevalence, establishing a firm diagnosis can be difficult as there is no single gold-standard test.
Spirometry, the first-line investigation, requires specialist staff, is time-consuming, challenging for patients as it requires forced blowing and is not very sensitive at picking up asthma. The second most common test, Fractional Exhaled Nitric Oxide (FeNO), a breath test which detects airway inflammation, only detects allergic asthma. It can also be suppressed by factors such as inhaled corticosteroids and smoking.
As a result, there are significant rates of under and over diagnosis. Oscillometry is a test that uses sound waves to measure how much resistance there is in the lungs when breathing normally. Increasing evidence is suggestive that it is more sensitive than spirometry at detecting narrowing of the small airways.
The aim of this study is to evaluate the diagnostic accuracy of a triple diagnostic approach with oscillometry, spirometry and FeNO using portable devices in adults referred with possible asthma.
We will be recruiting patients referred by GPs for suspected asthma across three centres: two secondary care respiratory clinics in St Mary's Hospital (SMH) at Imperial Health Care Trust (ICHT) and Nottingham University Hospitals NHS Trust (NUH), and a primary care diagnostic hub (Willesden Community Diagnostics Centre, WCDC). In addition to routine care (spirometry+/-reversibility and FeNO), patients will have oscillometry+/-reversibility testing, handheld capnography (carbon dioxide breath test), breath and nasal swab testing for novel asthma biomarkers.
The primary outcome will be evaluating the diagnostic accuracy of the triple diagnostic approach compared to the reference standard, which will be an adjudicated asthma diagnosis by two respiratory clinicians based on history and investigations.
Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.
The recruitment start and end dates are as follows:
Observational type: Validation of investigation /therapeutic procedures;
You can take part if:
You may not be able to take part if:
(I) Age < 18 years (II) A chest infection or exacerbation requiring antibiotics or steroids within 4 weeks of testing (III) Contraindications to spirometry testing (IV) Established or coded diagnosis of COPD (V) Pregnancy or lactating (VI) Other medical condition that in the opinion of the investigator would preclude compliance with the study protocoll (VII) Inability to understand English (VIII) Involvement in Clinical Trial of an Investigational Medicinal Product
Below are the locations for where you can take part in the trial. Please note that not all sites may be open.
The study is sponsored by Imperial College of Science, Technology and Medicine and funded by Asthma and Lung UK .
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Read full details
for Trial ID: CPMS 62029
You can print or share the study information with your GP/healthcare provider or contact the research team directly.
